Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes
Authors' conclusion
The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.
Study context
- Population
- db/db mice and HFD-streptozotocin induced diabetic mice; fenofibrate users and non-users in the Korean National Health Insurance database
- Participants
- 427,154 vs 427,154
- Comparison
- Fenofibrate vs no fenofibrate
- Fenofibrate usersn = 427,154
- Non-usersn = 427,154reference
- Outcome
- Cardiac effects in diabetic mice
Methodological detailsdb/db and HFD-streptozotocin diabetic mouse models, nationwide cohort (Korean National Health Insurance database)
- Db/db and HFD-streptozotocin diabetic mouse models
- Nationwide cohort (Korean National Health Insurance database)
Main finding
As reported in the abstract
- Fenofibrate reduced fibrosis and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| HF hospitalization · 4.22-year follow-up | 0.907 (0.824–0.998) | |
| 0.512Hazard ratio (log scale) |
Original publication
Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes. Cardiovasc Diabetol. Published 16 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →